Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
2 mg | In stock | $ 54.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 163.00 | |
25 mg | In stock | $ 333.00 | |
50 mg | In stock | $ 493.00 | |
100 mg | In stock | $ 732.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 98.00 |
Description | GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM). |
Targets&IC50 | LRRK2:19 nM |
In vitro | In rats, PKGNE-9605 administered orally at a dose of 1 mg/kg exhibited a total plasma clearance rate of 26 mL/min/kg, achieving an oral bioavailability of 90%. In BAC transgenic mice models expressing the human LRRK2 G2019S mutation associated with Parkinson's disease, GNE-9605, administered intraperitoneally at doses of 10 and 50 mg/kg, was able to inhibit the autophosphorylation of LRRK2 at Ser1292. |
In vivo | In vitro human MDR1 permeability data indicate that GNE-9605 exhibits favorable brain penetration in higher organisms. In biochemical (Ki: 2.0 nM) and cellular (IC50: 19 nM) assays, GNE-9605 demonstrates potent inhibitory activity against LRRK2. |
Molecular Weight | 449.83 |
Formula | C17H20ClF4N7O |
CAS No. | 1536200-31-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 82 mg/mL (182.3 mM)
Ethanol: 10 mg/mL (22.2 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GNE-9605 1536200-31-3 Autophagy LRRK2 oral bioavailability Leucine-rich repeat kinase 2 Parkinson's disease LRRK2 Ser1292 GNE 9605 autophosphorylation Inhibitor GNE9605 inhibit inhibitor